{"entity":{"id":"nct06452706","kind":"trial","name":"The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer","aka":[],"tldr":"A phase 2 trial of TQB2102 in advanced solid tumours, run by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., now recruiting.","summary":"The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer is a phase 2 interventional study registered as NCT06452706 by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., with 42 participants planned, started 2024-11-14 and due to reach its primary completion in 2026-06. Interventions recorded: TQB2102 for injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06452706","url":"https://clinicaltrials.gov/study/NCT06452706"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["tqb2102"],"companies":["sino-biopharm"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06452706","phase":"2","setting":"The Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection in Human Epidermal Growth Factor Receptor 2 (HER2) Negative Recurrent/Metastatic Breast Cancer","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","participation":[{"nct":"NCT06452706","source":"https://clinicaltrials.gov/study/NCT06452706","fetchedAt":"2026-10-07T16:54:41.796Z","studySha256":"386e5d4fb8ab181ba6f113ac199ecb1fc0e034d9306ec052b15c53d112f1f76a","overallStatus":"RECRUITING","lastUpdatePosted":"2024-11-19","leadSponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":42,"enrolmentType":"ESTIMATED","siteCount":16,"recruitingSiteCount":1,"countries":["China"]}],"started":"2024-11-14","startedType":"actual","enrolled":42,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06452706/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"tqb2102","kind":"drug","name":"TQB2102","route":"/drugs/tqb2102/"}],"company":[{"id":"sino-biopharm","kind":"company","name":"Sino Biopharmaceutical (Chia Tai Tianqing)","route":"/companies/sino-biopharm/"}]}}